• Explore /
  • Poster
  • / Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.

Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.

Abstract Poster

Authors

Mansoor Mirza

Mansoor Raza Mirza

The Finsen Centre 5073, Copenhagen, Denmark

Mansoor Raza Mirza , Gitte-Betina Nyvang , Bente Lund , Rene dePont Christensen , Theresa Louise Werner , Susanne Malander , Line Bjørge , Michael J. Birrer , Maarit Anttila , Gabriel Lindahl , Sakari Hietanen , Maria Dimoula , Ulla Peen , Kristine Madsen , Anja Knudsen , Synnove Staff , Nicole Buchner Vinum , Maj Kamille Kjeldsen , Elisabeth Avall-Lundqvist , Johanna Unelma Maenpaa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02354131

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6012)

DOI

10.1200/JCO.2020.38.15_suppl.6012

Abstract #

6012

Poster Bd #

183

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).

First Author: Ursula A. Matulonis

First Author: Fernanda Bronzon Damian

First Author: Philipp Harter

First Author: JUNG-YUN LEE